Skip to content

A Study to Detect Progression of Mass Effect From Unilateral Brain Lesions

Early Non-invasive Detection of Progression of Mass Effect From Unilateral Brain Lesions

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04745884
Enrollment
6
Registered
2021-02-09
Start date
2021-02-04
Completion date
2024-12-02
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-traumatic Hemispheric Brain Lesions

Brief summary

The purpose of this research is to gather information on the safety and effectiveness of the Brain4Care device for measuring intracranial pressure without invasive procedures.

Interventions

DEVICENon-invasive bilateral monitoring of ICP waveform

Brain4care non-invasive bilateral monitoring of ICP waveform

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients with non-traumatic hemispheric brain lesions deemed at risk for progression of mass effect and possible subfalcine and/or uncal herniation. * Patients admitted the Neuroscience ICU for serial neurological monitoring. * Patients whose care is not expected to include immediate surgical decompression.

Exclusion criteria

* Patients under the age of 18. * Patients who are unable to provide consent due to neurologic deficit and does not have a surrogate decision maker available to provide consent. * Known or suspected Pregnancy * Adults with cranial defects or that have undergone craniectomy

Design outcomes

Primary

MeasureTime frameDescription
Functional Outcome3 monthsFunctional outcome was assessed using the Modified Rankin Scale (mRS) which assesses functional outcomes in patients recovering from strokes. It consists of a 7-point ordinal scale ranging from 0 to 6 where 0=no symptoms and 6=dead with higher scores indicating a worse functional outcome.

Secondary

MeasureTime frameDescription
Imaging Utilizationwithin ICU admissionNumber of imaging scans

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAlejandro Rabinstein, MD

Mayo Clinic

Participant flow

Recruitment details

Recruitment stopped because bilateral monitoring was proven not sufficiently reliable for investigation

Baseline characteristics

Characteristic
Age, Continuous50 years
STANDARD_DEVIATION 4
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
5 Participants
Region of Enrollment
United States
6 participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
2 / 6
other
Total, other adverse events
0 / 6
serious
Total, serious adverse events
0 / 6

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026